FDA approves treatment for cutaneous T-cell lymphoma

Earlier this month, the US FDA approved the antibiotic histone deacetylase inhibitor romidepsin (marketed as Istodax injection) for treating patients with cutaneous T-cell lymphoma (CTCL) who have undergone at least one prior systemic therapy.

The FDA first fast-tracked the antibiotic as a potential anti-cancer agent in the treatment of CTCL five years ago, in 2004.

The FDA’s approval follows the publication of two multicenter, single-arm studies, one sponsored by Gloucester Pharmaceuticals (makers of Istodax) and another sponsored by the National Cancer Institute.

There were a number of adverse events reported following the conclusion of each study, including nausea, fatigue, infections, vomiting, and anorexia, as well as anemia, thrombocytopenia, electrocardiogram T-wave changes, neutropenia, and lymphopenia.

By Ross Bonander

More Articles

More Articles

Lymphomatoid Papulosis (LyP) is a rare skin disorder that involves cancerous looking skin lesions. It is more than a skin condition; it is the...

Lymphedema is abnormal swelling due to the presence of excess lymphatic fluid within the tissues. This swelling occurs when the...

Is there such a thing as an average cost of chemotherapy? No. Not even close. In order for there to be an average cost of chemotherapy, one would...

RICE is an acronym for an anti-cancer treatment that expresses a combination chemotherapeutic regimen. This regimen is written variously as "R+ICE...

The Follicular Lymphoma International Prognostic Index, or FLIPI, is a standardized guide to help oncological diagnosticians accurately calculate...

This entry looks at one of those types of lymphoma sometimes referred to simply as abdominal lymphoma. 'Lymphoma' is an umbrella term that...

Usually, even if a subtype of lymphoma is known to be indolent (slow-growing), it is considered a malignant...

One of the greatest fears of lymphoma survivors is that they’ll relapse and have to undergo treatment again. This fear is normal but awful to...

Large Cell Lymphoma (LCL) is typically an aggressive (fast growing) cancer of either the B cell or T cell type. They are one of the most common...

Indolent Lymphoma, or Indolent Non-Hodgkin’s Lymphomas (NHLs), are slow growing, low-grade cancers (as opposed to ...

A lymphoma diagnosis is not difficult to determine once a patient and doctor begin to look for signs of cancer...

A B cell is a type of lymphocyte that produces antibodies to fight infections. These are the most prevalent lymphocytes in the bloodstream and are...

What causes lymphoma is not well known. DNA mutations may be what causes lymphoma to develop but what triggers these mutations is...

Hodgkin's Lymphoma a.k.a. Hodgkin's Disease is a malignant (cancerous) growth of cells in the lymphatic system...

Lymphoma is a general term for cancer in the lymph system. The lymph system is made up of many cells and organs, including the lymph nodes, thymus...